🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million new cases per year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Testing Results and Global Access

According to results detailed in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This puts it on an comparable level with the current standard treatment, which involves an injection and a pill. The study enrolled nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have expressed hope. Access to a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.